BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...title="Interactive or visual content" frameborder="0" scrolling="no" style="width:100%;height:900px;"> Selina Koch AstraZeneca plc Arcus Biosciences Bristol-Myers Squibb Co. I-Mab Biopharma Akeso Biopharma Surface Oncology Inc. Novartis AG Corvus...
BioCentury | Jan 15, 2021
Management Tracks

Frates joins ALS company Amylyx; plus Artios, Valneva, Viravaxx

...U.K. on COVID-19. Celentano's track record includes vaccine-related roles with Merck & Co. Inc. (NYSE:MRK), Novartis AG...
BioCentury | Jan 15, 2021
Regulation

Jan. 14 Quick Takes: Lexicon rises on NDA timeline for heart failure program; plus: FDA COVID reports and updates from BeiGene, Merck, Bayer

...cell lung cancer (NSCLC), marking the PD-1 inhibitor’s third approved indication in China. On Monday, Novartis AG...
BioCentury | Jan 12, 2021
Deals

Novartis gains rights to BeiGene’s PD-1 in North America, Europe and Japan for $650M up front

...in mid-2019, BeiGene has found a partner in major-market territories for the PD-1 inhibitor in Novartis...
...million up front on Monday for rights in North America, Europe and Japan. Under Monday’s deal, Novartis AG...
...jointly develop tislelizumab in the U.S., Canada, EU, U.K., Mexico, Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan. Novartis...
BioCentury | Jan 12, 2021
Management Tracks

Editas shares sink as CSO Albright readies to depart; plus Arcutis, Precirix, Frazier

...build the company’s diagnostic and therapeutic radiopharmaceuticals pipeline leading to its $3.9 billion acquisition by Novartis AG...
BioCentury | Jan 9, 2021
Translation in Brief

Fusing camelid antibodies to toxin derivatives to treat botulism; plus BioNTech applies platform to multiple sclerosis, a molecule that stops axon degeneration and more

...lenalidomide and a target antigen for activation; the off-switch CARs contain a lenalidomide-induced degradable tag. Novartis...
...Inc. Eli Lilly and Co. Washington University School of Medicine in St. Louis Broad Institute of MIT and Harvard Novartis...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...data for anti-IL-1β mAb Ilaris canakinumab from Novartis AG...
BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

...Francis as CEO, effective Feb. 1. Francis was previously CEO of the Sandoz unit of Novartis AG...
BioCentury | Jan 7, 2021
Finance

Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

...Inc. Werewolf also added Randi Isaacs in November as CMO; she held clinical oncology roles at the Novartis...
BioCentury | Jan 1, 2021
Product Development

Not done yet. The COVID R&D Alliance has plenty on its plate for 2021

...& Melinda Gates Foundation, the Wellcome Trust and Novartis AG...
Items per page:
1 - 10 of 10571
BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...title="Interactive or visual content" frameborder="0" scrolling="no" style="width:100%;height:900px;"> Selina Koch AstraZeneca plc Arcus Biosciences Bristol-Myers Squibb Co. I-Mab Biopharma Akeso Biopharma Surface Oncology Inc. Novartis AG Corvus...
BioCentury | Jan 15, 2021
Management Tracks

Frates joins ALS company Amylyx; plus Artios, Valneva, Viravaxx

...U.K. on COVID-19. Celentano's track record includes vaccine-related roles with Merck & Co. Inc. (NYSE:MRK), Novartis AG...
BioCentury | Jan 15, 2021
Regulation

Jan. 14 Quick Takes: Lexicon rises on NDA timeline for heart failure program; plus: FDA COVID reports and updates from BeiGene, Merck, Bayer

...cell lung cancer (NSCLC), marking the PD-1 inhibitor’s third approved indication in China. On Monday, Novartis AG...
BioCentury | Jan 12, 2021
Deals

Novartis gains rights to BeiGene’s PD-1 in North America, Europe and Japan for $650M up front

...in mid-2019, BeiGene has found a partner in major-market territories for the PD-1 inhibitor in Novartis...
...million up front on Monday for rights in North America, Europe and Japan. Under Monday’s deal, Novartis AG...
...jointly develop tislelizumab in the U.S., Canada, EU, U.K., Mexico, Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan. Novartis...
BioCentury | Jan 12, 2021
Management Tracks

Editas shares sink as CSO Albright readies to depart; plus Arcutis, Precirix, Frazier

...build the company’s diagnostic and therapeutic radiopharmaceuticals pipeline leading to its $3.9 billion acquisition by Novartis AG...
BioCentury | Jan 9, 2021
Translation in Brief

Fusing camelid antibodies to toxin derivatives to treat botulism; plus BioNTech applies platform to multiple sclerosis, a molecule that stops axon degeneration and more

...lenalidomide and a target antigen for activation; the off-switch CARs contain a lenalidomide-induced degradable tag. Novartis...
...Inc. Eli Lilly and Co. Washington University School of Medicine in St. Louis Broad Institute of MIT and Harvard Novartis...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...data for anti-IL-1β mAb Ilaris canakinumab from Novartis AG...
BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

...Francis as CEO, effective Feb. 1. Francis was previously CEO of the Sandoz unit of Novartis AG...
BioCentury | Jan 7, 2021
Finance

Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

...Inc. Werewolf also added Randi Isaacs in November as CMO; she held clinical oncology roles at the Novartis...
BioCentury | Jan 1, 2021
Product Development

Not done yet. The COVID R&D Alliance has plenty on its plate for 2021

...& Melinda Gates Foundation, the Wellcome Trust and Novartis AG...
Items per page:
1 - 10 of 10571